Holen Sie sich die Stockscreener-App
46.61
2.10%
0.96
Handel nachbörslich:
46.61
Schlusskurs vom Vortag:
$45.65
Offen:
$45.34
24-Stunden-Volumen:
467.65K
Relative Volume:
0.83
Marktkapitalisierung:
$2.21B
Einnahmen:
$1.10B
Nettoeinkommen (Verlust:
$186.50M
KGV:
12.33
EPS:
3.7817
Netto-Cashflow:
$267.19M
1W Leistung:
+3.65%
1M Leistung:
-9.41%
6M Leistung:
-23.75%
1J Leistung:
-25.69%
1-Tages-Spanne:
$44.97
$46.72
1-Wochen-Bereich:
$44.46
$47.80
52-Wochen-Spanne:
$42.62
$71.07
Prestige Consumer Healthcare Inc Stock (PBH) Company Profile
Firmenname
Prestige Consumer Healthcare Inc
Sektor
Telefon
(914) 524-6800
Adresse
660 WHITE PLAINS RD., TARRYTOWN, NY
Compare PBH vs TAK, TEVA, HLN, ZTS, VTRS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBH
Prestige Consumer Healthcare Inc
|
46.61 | 2.21B | 1.10B | 186.50M | 267.19M | 3.7817 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Hochstufung | Sidoti | Neutral → Buy |
| 2024-12-09 | Herabstufung | Sidoti | Buy → Neutral |
| 2024-06-21 | Hochstufung | DA Davidson | Neutral → Buy |
| 2022-11-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-05-10 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-08-07 | Herabstufung | DA Davidson | Buy → Neutral |
| 2020-06-29 | Hochstufung | Sidoti | Neutral → Buy |
| 2020-04-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-04-07 | Fortgesetzt | Sidoti | Neutral |
| 2020-03-26 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-24 | Eingeleitet | Oppenheimer | Perform |
| 2020-03-19 | Hochstufung | DA Davidson | Neutral → Buy |
| 2019-01-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-12-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-06-02 | Hochstufung | Jefferies | Underperform → Hold |
| 2017-05-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-12-27 | Bestätigt | B. Riley & Co. | Buy |
| 2016-11-17 | Eingeleitet | Gabelli & Co | Buy |
| 2016-08-12 | Hochstufung | Sidoti | Neutral → Buy |
| 2016-03-08 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2016-02-05 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-11-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2014-04-28 | Bestätigt | B. Riley & Co. | Buy |
| 2014-04-28 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-09 | Eingeleitet | B. Riley & Co. | Buy |
Alle ansehen
Prestige Consumer Healthcare Inc Aktie (PBH) Neueste Nachrichten
Prestige Consumer Healthcare at small-cap virtual conference: growth plan intact - Investing.com India
Prestige Consumer Healthcare Inc. (PBH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Prestige Consumer Healthcare In (PBH) Stock Forecasts - Yahoo Finance
A Look at Prestige Consumer Healthcare Inc (PBH) After 3.8% Decl - GuruFocus
Responsive Playbooks and the PBH Inflection - Stock Traders Daily
Prestige Consumer Healthcare stock gains ahead of Sidoti event - AD HOC NEWS
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: 50% Upside Potential Amid Steady Revenue Growth - DirectorsTalk Interviews
Prestige Consumer Healthcare stock falls as analysts stay cautious - AD HOC NEWS
Prestige Consumer Healthcare stock falls after sharp drop toward 52-week low - AD HOC NEWS
Prestige Consumer Healthcare Inc (PBH) Shares Fall 3.2% -- What GF Score of 65 Tells Investors - GuruFocus
Prestige Consumer Healthcare stock holds steady as investors focus on recent earnings trend - AD HOC NEWS
PBH: Portfolio expansion and brand integration drive growth, with Clear Eyes recovery a key focus - TradingView
Prestige Consumer Healthcare at Barclays conference: growth via niche brands - Investing.com Canada
How InvestingPro Fair Value spotted Prestige Healthcare’s 43% drop By Investing.com - Investing.com India
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference - The Manila Times
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Assessing a Promising 29.74% Potential Upside - DirectorsTalk Interviews
Is This the Right Time to Add PBH Stock to Your Portfolio? - TradingView
Precision Trading with Prestige Consumer Healthcare Inc. (PBH) Risk Zones - Stock Traders Daily
Prestige Consumer Healthcare stock holds steady as investors watch valuation and growth - AD HOC NEWS
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test - Financial Times
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Exploring A 29% Upside Potential - DirectorsTalk Interviews
PBH Q2 2026 Earnings: EPS Beats Estimates by 10.01% as Stock Advances 2.46%Profit Guidance Range - dars.gov.et
PBH vs. SYK: Which Stock Is the Better Value Option? - Yahoo Finance
Prestige Consumer Healthcare Inc. (PBH) Investor Outlook: Exploring a 32% Upside Potential - DirectorsTalk Interviews
40,000 eye drop bottles recalled over potential contamination - Oman Observer
Nearly 40,000 eye drop bottles are recalled over potential contamination - The Seattle Times
40,000 bottles of eye drops across the US recalled over issues with sterility of product - inkl
Clear Eyes Maximum Itchy Eye Relief Recall: FDA Announces 39,060 Bottles RecalledNews and Statistics - IndexBox
Nearly 40,000 eye drops recalled nationwide over possible contamination - Fox Business
Great Lakes Advisors LLC Takes $2.98 Million Position in Prestige Consumer Healthcare Inc. $PBH - MarketBeat
Nearly 40,000 bottles of eye drops recalled nationwide over possible contamination - FOX 32 Chicago
Clear Eyes eye drops recalled over sterility concerns - qz.com
FDA announces nationwide recall of nearly 40,000 Clear Eyes eye-drop bottles over potential contamination - The Economic Times
Is Prestige Consumer Healthcare’s (PBH) Upgraded 2027 Outlook and Halted Buybacks Reframing Its Growth Story? - webull.com
Rice Hall James & Associates LLC Acquires Shares of 689,692 Prestige Consumer Healthcare Inc. $PBH - MarketBeat
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops - Glance by Eyes On Eyecare
Prestige Consumer Healthcare (PBH) Q1 2027 Earnings Call Transcript - AOL.com
Prestige Consumer Healthcare (PBH) Stock Analysis: Exploring a 31.96% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Prestige Consumer Healthcare (PBH) Holds Near $51.38 as Range-Bound Trading PersistsVolume Dry Up - vinanet.vn
ETFs Investing in Prestige Consumer Healthcare Inc Stocks - TradingView
Prestige Consumer Healthcare Announces Operations Leadership Transition - The Globe and Mail
Prestige Consumer Healthcare's Jeffrey Zerillo to Retire as SVP, Operations - TradingView
Prestige Consumer Healthcare Inc. Announces Retirement of Jeffrey Zerillo from Senior Vice President, Operations, Effective August 14, 2026 - marketscreener.com
Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover? - Yahoo Finance
Finanzdaten der Prestige Consumer Healthcare Inc-Aktie (PBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):